secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001746473-25-000149
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics discontinues bexotegrast in IPF; Q2 net loss narrows to $43.3M
--------------------------------------------------------------------------------

- Bexotegrast development in IPF stopped due to unfavorable risk-benefit; full BEACON-IPF data to be published.
- Phase 1 trial of PLN-101095 in solid tumors ongoing; data from top two dose cohorts expected by end of 2025.
- Workforce restructuring largely complete; cash, cash equivalents and short-term investments at $264.4M as of June 30.
- Q2 R&D expenses fell to $32.2M from $45.6M; G&A dropped to $13.4M from $15.0M.
- Net loss of $43.3M improved from $55.9M in prior-year quarter, driven by restructuring and trial discontinuation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000149/0001746473-25-000149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000149/plrx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001746473-25-000149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer